InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

Current share price for RCE : $0.345 0.01 (2.99%)+

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$105 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2022 11:06AM $1.175 $0.345 fallen by 70.64%
$105 Positive Safety Data from Second Cohort of PI Clinical Trial 18 Jan 2022 1:23PM $1.300 $0.345 fallen by 73.46%
$105 Positive Safety Data from Phase 1 Clinical Trial 7 Jan 2022 10:31AM $1.045 $0.345 fallen by 66.99%
$105 Patients to be Dosed in Ph 1 IV Clinical Trial of R327 15 Dec 2021 9:24AM $0.945 $0.345 fallen by 63.49%
$105 Update on Phase I/II Clinical Trial for Burn Wound Infection 7 Dec 2021 9:43AM $0.860 $0.345 fallen by 59.88%
$105 Results of Meeting 22 Nov 2021 3:36PM $0.890 $0.345 fallen by 61.24%
$105 AGM Presentation 22 Nov 2021 9:57AM $0.850 $0.345 fallen by 59.41%
$105 Opening R&D Address at World AMR Congress 8 Nov 2021 10:30AM $0.945 $0.345 fallen by 63.49%
$105 Appendix 4C and Activity Report 29 Oct 2021 11:48AM $0.940 $0.345 fallen by 63.30%
$105 Ethics Approval to Start Phase 1 Intravenous Clinical Trial 25 Oct 2021 10:17AM $0.930 $0.345 fallen by 62.90%
$105 Letter to Shareholders - Annual General Meeting 22 Oct 2021 12:40PM $0.925 $0.345 fallen by 62.70%
$105 Notice of General Meeting/Proxy Form 22 Oct 2021 12:33PM $0.925 $0.345 fallen by 62.70%
$105 Reinstatement to Official Quotation 12 Oct 2021 2:09PM $0.915 $0.345 fallen by 62.30%
$105 Court Orders Granted 12 Oct 2021 2:09PM $0.915 $0.345 fallen by 62.30%
$105 Suspension from Official Quotation 12 Oct 2021 9:59AM $0.915 $0.345 fallen by 62.30%
$105 Application for quotation of securities - RCE 8 Oct 2021 1:58PM $0.915 $0.345 fallen by 62.30%
$105 Court application and delayed cleansing notice 8 Oct 2021 1:57PM $0.915 $0.345 fallen by 62.30%
$105 Trading halt 8 Oct 2021 1:11PM $0.915 $0.345 fallen by 62.30%
$105 Pause in Trading 8 Oct 2021 12:21PM $0.915 $0.345 fallen by 62.30%
$105 R327 Phase I Clinical Trial Registered on ANZCTR 30 Sep 2021 1:42PM $0.980 $0.345 fallen by 64.80%
$105 Appendix 4G 31 Aug 2021 5:42PM $0.755 $0.345 fallen by 54.30%
$105 Annual Report to shareholders 31 Aug 2021 5:42PM $0.755 $0.345 fallen by 54.30%
$105 Appendix 4E 31 Aug 2021 5:42PM $0.755 $0.345 fallen by 54.30%
$105 Change in substantial holding 16 Aug 2021 8:00AM $0.900 $0.345 fallen by 61.67%
$105 Recce Receives Further Innovation Connections Grant 11 Aug 2021 12:40PM $0.905 $0.345 fallen by 61.88%

326 - 350 of 730 results

Page 14 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.